The March agreement between GNC and the New York attorney general’s office that paves the way for GNC to use DNA barcode testing—at least for incoming raw materials if not for finished-product extracts—raises several questions about how testing protocols may reshape the supplements industry. Not least of those is whether the agreement—even if it is good news for GNC in the short term (its stock price rose 7 percent on news of the compact)&mda
All access premium subscription
This content requires a subscription to Nutrition Business Journal.
As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.
Email [email protected] for more information about subscribing.